
Corcept Claims Survival Benefit in ALS Despite Missed Endpoint
Corcept Therapeutics’ investigational cortisol modulator dazucorilant failed to boost functional performance in patients with amyotrophic lateral sclerosis—but the biotech dug into the data Thursday and came away with overall survival benefits. Analysts at …